Long-term efficacy and safety of varenicline for smoking cessation: A Systematic review and meta-analysis of randomized controlled trials

Journal of Public Health (Germany)

Volumn 20, Issue 4, 2012, Pages 355-365

  Huang, Yubei ^a   Li, Weiqin ^b   Yang, Li ^c   Jiang, Yuan ^d   Wu, Yangfeng ^a,e  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Tianjin Women and Children's Health Center   (China)

^c SOOCHOW UNIVERSITY   (China)

^d Chinese Center of Disease Prevention and Control   (China)

^e GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

Meta analysis; Smoking cessation; Systematic review; Trials; Varenicline

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; NICOTINE; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; AGE; ANXIETY; ASIAN; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; EXPIRED AIR; FATIGUE; FLATULENCE; FOLLOW UP; HUMAN; INSOMNIA; IRRITABILITY; META ANALYSIS; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SEX DIFFERENCE; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; VOMITING; XEROSTOMIA;

EID: 84863982454     PISSN: 09431853     EISSN: 16132238     Source Type: Journal    
DOI: 10.1007/s10389-011-0476-5     Document Type: Review

References (64)

1. Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S (2009) Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Invest 29(10):655-665
2. Aubin H, Bobak A, Britton J, Oncken C, Billing C, Gong J, Williams K, Reeves K (2008) Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 63(8):717-724
3. Begg C, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088-1001
4. Benowitz N, Pérez-Stable E, Herrera B, Jacob P (2002) Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 94(2):108-115
5. Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork A, Aubin H (2009) Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries. Eur J Public Health 19(6):650-654
6. Bolliger C, Issa J, Posadas V, Safwat T, Abreu P, Correia E (2010) A randomized trial of varenicline for smoking cessation in Latin America, Africa and the Middle East. Am J Respir Crit Care Med 181(1-MeetingAbstracts):A2648
7. Cahill K, Stead L, Lancaster T (2011) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev (2): CD006103
8. CCDC (2006) China's "Smoking and health" report, 2006. China Cancer Foundation, China Center for Disease Control and Prevention, China Tobacco Control Association, China Medical Society, China Health Education Association, China Anti-Cancer Association, National Office for Cancer Prevention and Treatment, Ministry of Health PRC, Beijing, China
9. CCDC (2007) 2007 China tobacco control report: create a smoke-free environment-enjoy a healthy life. Office of the Leading Small Group for Implementation of the Framework Convention on Tobacco Control, China Centers for Disease Control and Prevention, Ministry of Health, PRC, Beijing, China
10. CCDC (2009) The key information of Fourth National Health Services Survey in China. http://www.chinacdc.net.cn/n272442/n272530/n272742/29573.html. Cited 6 April 2011
11. CCDC (2011) China global adult tobacco survey (GATS) report, 2010. National Office of Tobacco Control, China Centers for Disease Control and Prevention, Beijing
12. CDC (2004) Cigarette smoking among adults: United States, 2002. MMWR Morb Mortal Wkly Rep 53(20):427-431
13. CMOH (2009) An Analysis Report of National Health Services Survey in China, 2008. Center for Health Statistics and Information, Ministry of Health, PRC. Chinese Academy Science & Peking Union Medical College Press, Beijing, China
14. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics 56(2):455-463
15. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634
16. Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M (2010) Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. doi:10.1007/s001090000086
17. FDA (2009) The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics). U. S. Food and Drug Administration. Available: http://www.fda.gov/downloads/Drugs/DrugSafety/ DrugSafetyNewsletter/UCM107318.pdf. Cited 6 April 2011
18. Foulds J, Gandhi K, Steinberg M, Richardson D, Williams J, Burke M, Rhoads G (2006) Factors associated with quitting smoking at a tobacco dependence treatment clinic. Am J Health Behav 30(4):400-412
19. Gonzales D, Rennard S, Nides M, Oncken C, Azoulay S, Billing C, Watsky E, Gong J, Williams K, Reeves K (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296(1):47-55
20. Gu D, Kelly T, Wu X, Chen J, Samet J, Huang J, Zhu M, Chen J, Chen C, Duan X, Klag M, He J (2009) Mortality attributable to smoking in China. NEJM 360:150-159
21. Gunnell D, Irvine D, Wise L, Davies C, Martin R (2009) Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database. BMJ. doi:10.1136/bmj.b3805
22. Hays J, Croghan I, Schroeder D, Ebbert J, Hurt R (2011) Varenicline for tobacco dependence treatment in recovering alcoholdependent smokers: an open-label pilot study. J Subst Abus Treat 40(1):102-107
23. Higgins J, Thompson S (2002) Quantifying heterogeneity in a metaanalysis. Stat Med 21(11):1539-1558
24. Higgins J, Thompson S (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23(11):1663-1682
25. Higgins J, Thompson S, Deeks J, Altman D (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560
26. Hughes J, Stead L, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev (1): CD000031
27. Hyland A, Li Q, Bauer J, Giovino G, Steger C, Cummings K (2004) Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicot Tob Res Suppl 3:S363-S369
28. Hymowitz N, Cummings K, Hyland A, Lynn W, Pechacek T, Hartwell T (1997) Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control Suppl 2:S57-S62
29. Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D, McQuay H (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1-12
30. Jorenby D, Hays J, Rigotti N, Azoulay S, Watsky E, Williams K, Billing C, Gong J, Reeves K (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296(1):56-63
31. Kim K, Johnson J, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44(10):1083-1105
32. Lancaster T, Stead L (2005a) Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev (2): CD001292
33. Lancaster T, Stead L (2005b) Self-help interventions for smoking cessation. Cochrane Database Syst Rev (3): CD001118
34. Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, Clarke M, Devereaux P, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
35. Liu B, Peto R, Chen Z, Boreham J, Wu Y, Li J, Campbell T, Chen J (1998) Emerging tobacco hazards in China: 1. retrospective proportional mortality study of one million deaths. BMJ 317:1411-1422
36. McClure J, Swan G, Jack L, Catz S, Zbikowski S, McAfee T, Deprey M, Richards J, Javitz H (2009) Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 24(5):563-569
37. Nakajima M (2007) Smoking behavior and related cancers: the role of CYP2A6 polymorphisms. Curr Opin Mol Ther 9(6):538-544
38. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon J, McLeod H, Yokoi T (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80(3):282-297
39. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves K (2007) Efficacy and tolerability of varenicline, an (alpha) 4(beta) 2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 29 (6):1040-1056
40. Niaura R, Hays J, Jorenby D, Leone F, Pappas J, Reeves K, Williams K, Billing C (2008) The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 24(7):1931-1941
41. NICE (2007) Varenicline for smoking cessation. National Institute for Health and Clinical Excellence. http://www.guideline.gov/content.aspx?id011305. Cited 6 April 2011
42. Nides M, Oncken C, Gonzales D, Rennard S, Watsky E, Anziano R, Reeves K (2006) Smoking cessation with varenicline, a selective (alpha) 4(beta) 2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166 (15):1561-1568
43. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing C, Anziano R, Reeves K (2006) Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166(15):1571-1577
44. Pfizer (2009) Evaluation of the efficacy of varenicline on cognition, safety, tolerability and pharmacokinetics in subjects with mild-tomoderate Alzheimer's disease. http://clinicaltrials.gov/ct2/show/NCT00744978. Cited 6 April 2011
45. Philip N, Carpenter L, Tyrka A, Whiteley L, Price L (2009) Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry 70(7):1026-1031
46. Ra Raw M, McNeill A, Arnott D (2006) Varenicline: guidance for health professionals on a new prescription-only stop smoking medication. Available: http://www.stop-tabac.ch/pdf/ASHVareniclineguidance.pdf. Cited 6 April 2011
47. Rigotti N, Pipe A, Benowitz N, Arteaga C, Garza D, Tonstad S (2010) Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121(2):221-229
48. Secker-Walker R, Gnich W, Platt S, Lancaster T (2002) Community interventions for reducing smoking among adults. Cochrane Database Syst Rev (3): CD001745
49. Smith R, Lindenmayer J, Davis J, Cornwell J, Noth K, Gupta S, Sershen H, Lajtha A (2009) Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 110(1-3):149-155
50. Smith B, Peters M, Fitridge R, Esterman A, Litt J, Horowitz J, Koblar S, Jannes J, Veale A, Goldsworthy S, Brinn M, Labiszewski N, Carson K (2011) Varenicline tartrate and counselling versus counselling alone in a randomised controlled trial for inpatient smoking cessation: 6 month interim results. Am J Respir Crit Care Med 183(1-MeetingAbstracts):A5445
51. Staff CPGTTUaDUPLa (2008) A clinical practice guideline for treating tobacco use and dependence: 2008 update: a U. S. public health service report. Am J Prev Med 35(2):158-176
52. Stapleton J, Watson L, Spirling L, Smith R, Milbrandt A, Ratcliffe M, Sutherland G (2008) Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 103(1):146-154
53. Stead L, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (1): CD000146
54. Tashkin D, Rennard S, Hays J, Ma W, Lawrence D, Lee T (2011) Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 139(3):591-599
55. Thomas R, Perera R (2006) School-based programmes for preventing smoking. Cochrane Database Syst Rev 3:CD001293
56. Tonstad S, Tonnesen P, Hajek P, Williams K, Billing C, Reeves K (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296(1):64-71
57. Tsai S, Cho H, Cheng H, Kim C, Hsueh K, Billing C, Williams K (2007) A randomized, placebo-controlled trial of varenicline, a selective (alpha) 4(beta) 2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 29 (6):1027-1039
58. Tsukahara H, Noda K, Saku K (2010) A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J 74(4):771-778
59. Wang C, Xiao D, Sun Y, Huang K, Zhi X, Jiang Y (2008) Chinese clinical practice guideline for treating tobacco use and dependence (in Chinese). Int J Respir 28(16):961-970
60. Wang C, Xiao D, Chan K, Pothirat C, Garza D, Davies S (2009) Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 14(3):384-392
61. WHO (2008) WHO report on the global tobacco epidemic, 2008: MPOWEER. World Health Organization, Geneva
62. Williams K, Reeves K, Billing C, Pennington A, Gong J (2007) A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 23(4):793-801
63. Yang G, Fan L, Tan J, Qi G, Zhang Y, Samet J, Taylor C, Becker K, Xu J (1999) Smoking in China: findings of the 1996 National Prevalence Survey. JAMA 282(13):1247-1256
64. Yang G, Ma J, Liu N, Zhou L (2005) Smoking and passive smoking in Chinese, 2002. Zhonghua Liu Xing Bing Xue Za Zhi 26(2):77-83